Global (7MM) sales for the cystic fibrosis (CF) market are forecast by GlobalData to grow from $2.1B in 2015 to $7.6B in 2025. The majority of sales are expected to come from the US, which will represent 68% of the market by 2025. The sales growth during the 2015–2025 forecast periods will be primarily driven by the launches of Vertex’s cystic fibrosis transmembrane conductance regulator (CFTR) modulator ivacaftor/tezacaftor.
The CFTR modulator drug class is expected to grow from 43.3% of total CF drug sales in 2015 to 81.2% of total CF drug sales in 2025. Vertex Pharmaceuticals will continue to dominate the CF drug space as it has two marketed CFTR modulators and is expected to launch third CFTR modulator during the forecast period, fulfilling some of the major unmet needs of the CF population.
Major drivers of the growth of the CF market over the forecast period will include:
- The introduction of the high-priced, disease-modifying drug Orkambi (ivacaftor + lumacaftor) in 2015, followed by the introduction of novel, high-priced, disease-modifying CFTR modulators during the forecast period.
- The continued growth of the number of CF patients due to the overall population growth and continuously increasing life expectancy of CF patients
Major barriers to the growth of the CF market will include:
- The high price of CFTR modulators, which may prevent their reimbursement by local health authorities and health insurance companies.
· The complexity inherent in the pathophysiology and molecular mechanisms involved in the development of CF, which will continue to hinder the development of safe and effective agents for the management of CF.
OpportunityAnalyzer: Cystic Fibrosis – Opportunity Analysis and Forecasts to 2025
Price: $10,995 (Single User License)
Published: April 2017
Report Format: electronic pdf
Asia-Pacific asthma therapeutics market is forecast to grow significantly over the forecast period, from $4.1 billion in 2016 to a projected value of $6 billion by 2023, at a compound annual growth rate (CAGR) of 5.4%.
The aging population is growing significantly, which will increase the asthma prevalence in the Asia-Pacific region. In addition, the severity of asthma increases with age, meaning elderly patients require more medications to control their asthma symptoms, which will drive the market. In addition to the aging population, other factors such as increases in air pollution, dust, and pollen levels also contribute to the increase in asthma prevalence. Air pollution leads to both the occurrence of the disease and its exacerbation in children, and there is growing evidence of asthma symptoms in children who live near roadways in high traffic zones (Kopnina, 2012).
Biologics Growing in Prominence in Asthma Treatment
While the asthma market is dominated almost exclusively by small molecules, the pipeline is more varied. It consists of 65% small molecules, but there are also 67 biologics, equating to 24% of the pipeline.
The rise in biologic development is possibly due to the success of Xolair (omalizumab), one of the currently marketed monoclonal antibodies (mAb) in asthma therapeutics, which reached blockbuster status in 2014. Xolair is a recombinant humanized anti-IgE, and was the first humanized therapeutic mAb to be indicated for asthma. It was approved by the FDA in 2003 as an add-on therapy for adults and adolescents aged 12 and over with moderate-to-severe allergic asthma and symptoms not adequately controlled with inhaled corticosteroids (ICS).
The report “Asthma Therapeutics in Asia-Pacific Markets to 2023 – High Prevalence and Highly Priced Existing & Upcoming Biologics will Drive the Market” provides an introduction to asthma, detailing the epidemiology, etiology, diagnostic techniques, pathophysiology and prognosis for patients. An analysis of current treatment algorithms and options is also included.
Price: $4,995 (Single User License)
Published: June 2017
Publisher: GBI Research
Report Format: electronic pdf